-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Manufacturers of specialty therapies aim to ensure patients can access, initiate, and remain on therapy while demonstrating clinical and economic value to payers, providers, and regulators. That means measuring time-to-therapy, initiation rates, prior-authorization success, adherence/persistence, patient support program (PSP) engagement, clinical outcomes, and downstream resource use — and linking those metrics to commercial and health-outcome
This spring, I explored the applications of agentic AI in pharmaceutical commercialization teams. Many organizations are piloting these tools, but the success of any rollout depends less on technical capabilities and more on building a robust trust model that mitigates risk. Agentic AI—systems capable of autonomously reasoning, planning, and executing multi-step tasks—has quickly emerged as
Merilytic Health 